亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Flagellin-Based Vaccine Adjuvants

詳細技術說明
Flagellin may be delivered as a purified protein for its adjuvant effect.Alternatively flagellin can be delivered as flagellin-expressing cells, which continuously release flagellin for a period of time.Flagellin can be expressed by tumor-antigen presenting cells that are lethally irradiated, hence localizing and prolonging the T-cell activation effect for tumor antigens.Flagellin adjuvants may enhance therapeutic tumor vaccine efficacy for many tumor types, including leukemia and melanoma.
*Abstract
A barrier to the development of therapeutic cancer vaccines is tolerance of T-cells to tumor antigens.Flagellin is a bacterial protein that inhibits tolerance to tumor antigens, and can stimulate tumor antigen-presenting cells to activate T-cells.Experiments in mice in vivo show that flagellin induces the pro-inflammatory cytokine IL-12 and inhibits the anti-inflammatory cytokine IL-10, and inhibits tolerance to antigens.Flagellin may thus constitute an effective adjuvant to be administered with tumor vaccines to overcome tolerance.
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備